Nervous Disorder TRIZ Cases

Rice okara stabilizes volatile lavender oil and improves solubility, absorption, and protection from gastric degradation for mild insomnia use.

ADAMTS13 cleaves ultra-large VWF multimers to reduce vaso-occlusive crises, inflammation, and lung injury in sickle cell disease.

PDE5 inhibitors selectively block context-specific fear memory in PTSD while preserving novel object recognition and spatial memory.

Cell-penetrating peptide conjugates help exendin-4 cross the blood-brain barrier, extend half-life, and reduce neuroinflammation.

A tripartite PROTAC architecture expands IRAK4 degrader diversity while enabling selective ubiquitination and safer inflammatory disease therapy.

Specific Fc substitutions such as T260L and T260N improve Fc receptor binding and ADCC while remaining compatible with antibody production.

A calorie- and protein-restricted fasting-mimicking diet boosts stem cell function, supports tissue regeneration, and eases age-related decline.

Encapsulating trans-crocetin and related carotenoid salts in liposomes improves stability, bioavailability, and delivery in sepsis and hypoxia.

Multiple Risdiplam crystalline forms improve stability, solubility, and handling while supporting more reliable pharmaceutical processing.

Specific trofinetide crystal and hydrate forms improve chemical and storage stability while supporting reproducible pharmaceutical formulation.

Specific xanthophylls from microalgae protect neurons against cell death and inflammation to help treat neurodegeneration and cognitive decline.

A ketal-protected four-step Ganaxolone synthesis improves regioselectivity and avoids acid/base degradation to deliver pharmaceutical-quality purity.

Selective oral bacteriophages reduce harmful gut bacteria, support beneficial microbes, and ease gastrointestinal inflammation without dysbiosis.

Novel mPTP inhibitor compounds tune structure for brain penetrance and selectivity while preventing cell death in neurodegenerative disease.

Novel 9H-fluorene derivatives combine BuChE, BACE1, and beta-amyloid inhibition in one compound to address Alzheimer's multifactorial pathology.

Consensus-sequence LanCL-binding peptides deliver analgesic, anti-inflammatory, and anti-microbial activity across ageing-, damage-, and stress-related conditions.

Targeted heterocyclic and ethylamine substitutions reduce mescaline side effects and toxicity while preserving therapeutic receptor activity.

Salt formation with succinate or citrate makes hexylamine more palatable, stable, and suitable for oral compositions.

Insulin-secreting mesenchymal stem cells promote Schwann cell proliferation and remyelination to treat Charcot-Marie-Tooth disease.

Structural changes to a sulfonylurea derivative improve brain penetration and reduce cerebral edema and intracranial pressure after stroke.

Specific anti-FAM19A5 CDR sequences improve target binding to reduce fibrosis, slow tumor progression, and modulate neural activity.

Allogeneic umbilical cord MSC infusion targets brain inflammation in ASD, aiming to improve core social communication with good tolerability.

A THC and CBD formulation reduces stuttering and Tourette symptoms while minimizing side effects seen with traditional drug therapies.

Wet granulation with hydrophilic excipients and disintegrants balances tablet hardness, rapid oral disintegration, and storage stability.

Up-regulating ISG genes with small molecules or interferons shifts mammalian repair from scar-forming fibrosis toward functional tissue regeneration.

Apoaequorin preconditions neurons by buffering calcium and lowering TNFα, reducing inflammation with fewer side effects.

Chemically modified GHB prodrugs improve oral bioavailability and sustain therapeutic plasma levels, reducing divided dosing burden.

A solid R-beta-hydroxybutyrate composition enables faster ketosis support without the harmful electrolyte load of high-dose salts.

Specific heavy-chain sequence changes improve by-product separation while preserving PD-1 and CD19 binding for autoimmune disease treatment.

SNAC, MCFA, and amino acids help protect polypeptides in the stomach and improve oral absorption, bioavailability, and dosing efficiency.

A heat-labile gelling agent and thermal stabilizer create high viscosity during tampering, blocking drug extraction and abuse.

Affinity-modified IgSF domains enable non-competitive binding to multiple partners, improving immune synapse modulation for cancer and immune disorders.

A single binding arm prevents C1q cross-linking, reducing infusion-related reactions while preserving complement inhibition and half-life.

A tuned anionic-cationic-neutral lipid ratio directs mRNA to spleen antigen-presenting cells while limiting liver and lung expression.

Cell-penetrating PDE5 inhibitors suppress Aβ aggregation, activate autophagy, and help remove intracellular oligomers linked to Alzheimer disease.

Fluorinated sEH inhibitors improve CYP metabolic stability while crossing the blood-brain barrier for CNS seizure protection.

FAAH-driven CB1 activation lowers sphingomyelin buildup in lysosomal storage disorders while helping limit neuronal damage and cognitive decline.

Targeted CTLA4 amino acid substitutions improve B7-1 and B7-2 binding, boosting T-cell inhibition for immune disorder therapy.

By tuning POZ polymer characteristics and degradable linkages, this case controls drug release rates to extend half-life and reduce adverse effects.

Enzymatic treatment of Ashwagandha improves sleep latency, duration, and NREM quality while avoiding dependence and daytime sleepiness.

Piperazine and piperidine CaV3.2 blockers curb depolarization-driven calcium influx to relieve neuropathic pain with fewer side effects.

Subtype-selective M4 antagonist compounds improve neurological symptom control while reducing cognitive and gastrointestinal side effects.

Epitope-specific anti-Tau antibodies bind pathological Tau conformers and phosphorylation states to improve therapeutic specificity in tauopathies.

A single bicistronic AAV improves CNS co-delivery of HEXA and HEXB, enabling stable hexosaminidase expression for Tay-Sachs and Sandhoff therapy.

Engineered humanized anti-Aβ binding delays familial Alzheimer's symptoms and slows cognitive decline with fewer safety concerns.

Protein-like polymers bind, mimic, or disrupt tau to control aggregation and phase-separated states for tauopathy treatment or detection.

A dual-drug regimen targets insulin sensitivity and lipid metabolism to cut amyloid β buildup and visceral adiposity before irreversible decline.

Cross-specific glycosylated IgM binds IgG and complexing molecules to trigger IgG degradation, helping restore homeostasis in autoimmune disease.

Monoclonal anti-JCV antibodies block viral binding and replication, offering a prophylactic and therapeutic route for PML in immunosuppressed patients.

Engineered MSCs add adhesion ligands, immunomodulators, and IL-10 to improve inflamed tissue homing, persistence, and potency.